Appili Therapeutics Inc. (OTCMKTS:APLIF) Sees Large Growth in Short Interest

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 121,200 shares, an increase of 584.7% from the February 28th total of 17,700 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 83,500 shares, the short-interest ratio is presently 1.5 days.

Appili Therapeutics Stock Performance

Shares of OTCMKTS:APLIF opened at $0.03 on Friday. The firm has a market cap of $3.41 million, a price-to-earnings ratio of -1.41 and a beta of -0.55. The business has a 50-day simple moving average of $0.02 and a two-hundred day simple moving average of $0.02. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.05.

Appili Therapeutics Company Profile

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.